Minimal residual disease in myeloma by flow cytometry: Independent prediction of survival benefit per log reduction

Blood

Volumn 125, Issue 12, 2015, Pages 1932-1935

  Rawstron, Andy C ^a   Gregory, Walter M ^b   De Tute, Ruth M ^a   Davies, Faith E ^c   Bell, Sue E ^b   Drayson, Mark T ^d   Cook, Gordon ^a   Jackson, Graham H ^e   Morgan, Gareth J ^c   Child, J Anthony ^b   Owen, Roger G ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; M PROTEIN; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYELOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR INVASION; AGED; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SENSITIVITY AND SPECIFICITY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925355047     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-590166     Document Type: Article

References (13)

1. Paiva B, Gutiérrez NC, Rosiñol L, et al PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study Groups. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687-691.
2. Paiva B, Vidriales M-B, Cerveró J, et al GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-4023.
3. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540-2547.
4. Munshi NC, Anderson KC. Minimal residual disease in multiple myeloma. J Clin Oncol. 2013;31(20):2523-2526.
5. Landgren O, Gormley N, Turley D, et al. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium. Am J Hematol. 2014;89(12):1159-1160.
6. Morgan GJ, Davies FE, Gregory WM, et al National Cancer Research Institute Haematological Oncology Clinical Studies Group. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012;97(3):442-450.
7. Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28(3):525-542.
8. Rawstron AC, Orfao A, Beksac M, et al European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431-438.
9. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980-988.
10. Morgan GJ, Davies FE, Gregory WM, et al. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013;19(21):6030-6038.
11. De Tute RM, Rawstron AC, Child JA, et al. Impact of minimal residual disease and induction therapy on outcome post ASCT: insights from the MRD Myeloma IX trial. Clin Lymphoma Myeloma Leuk. 2013;13:S45.
12. Sarasquete ME, García-Sanz R, González D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365-1372.
13. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073-3079.